1414386-05-2

Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis[1][2][3][4].

IL-17A; IL-17F

[1] Torres T, et al. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25(7):751-4. DOI:10.1080/13543784.2016.1187130
[2] Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289(14):4304-4327. DOI:10.1111/febs.15809
[3] Gao W, et al. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. Front Immunol. 2023 May 25;14:1151977. DOI:10.3389/fimmu.2023.1151977
[4] Vanheusden K, et al. Pre-clinical proof-of-concept of ALX-0761, a Nanobody? neutralizing both IL-17A and F in a cynomolgus monkey collagen induced arthritis model[C]//ARTHRITIS AND RHEUMATISM. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: Wiley-Blackwell, 2013, 65: S543-S543.